Prevalence of integron class 1, 2, 3 among multidrug - Resistant Pseudomonas aeruginosa
Multi drug-resistant bacteria have recently arisen increasingly in the arena, creating significant challenges in the treatment of bacterial infections worldwide. Pseudomonas aeruginosa, the clinically significant bacterium causes nosocomial infections. This study aimed to screen out class 1, 2, and 3 integrons among multi drug resistance Pseudomonas aeruginosa infections. This study selectively targetted Pseudomonas aeruginosa in clinical specimens identified primarily by conventional biochemical tests between December 2023 and March 2024. confirm identification and analyze the antibiotic resistance patterns of these bacteria by using the VITEK 2 Compact system. Mobile resistance genes were screened using intI1, intI2, and intI3 gene-specific primers and conventional PCR. The current study included the collection of 150 clinical specimens from patients suffering from (burns, diabetic foot ulcer, and wound infections) and the findings based on phenotyping characterization by using, nutrient, blood, Macconky agar media, then selective media cetrmide agar seplemented with nalidixic acid to improve selectivity isolation, biochemical tested, final identification to Pseudomonas aeruginosa isolates done by automatic VTEK-2 compact device which included 64 biochemical checks on Gram-negative-ID cards showed that only 25.3% (38/150) belong to Pseudomonas aeruginosa, where 60 % (90/150) gave other bacterial growth and 14.6% (22/150) no bacterial growth. Antimicrobial susceptibility test was performed on 38 Pseudomonas aeruginosa clinical isolates to evaluate minimum inhibitary concentration (MIC) levels according to clinical and laboratory standards institute (CLSI) guide 2024 by Viteck 2 compact system AST-GN76 (Pseudomonas aeruginosa) cards and software version 5.01 to know the susceptibility of 38 Pseudomonas aeruginosa to various antibacterials agents revealed that these isolates had resistance rate to norfloxacin 65.78% (25/38), ciprofloxacin 39.47%(15/38), meropenem 28.94%(11/38), imipenem 60.52%(23/38), gentamycin 92.10%(35/38), amikacin 100%(38/38), ceftazidime 89.4%(34/38), cefepime 86.84%(33/38 ) and cefotaxime 84.21(32/38) and observed 5 (13.15%) were multidrug resistance Pseudomonas aeruginosa that are resistance to all antibiotic used in this study. polymerase chain reaction ( PCR) results in all 5 multi drug resistance Pseudomonas aeruginosa carried intgron class 1,2 and 3 gene 100 (5/5) whereas none of these isolates carried intI2,intI3 gene. Mobile multiple resistance genes are suggested as the influential player in the growing multiple resistance of P. aeruginosa. intI1gene was concluded as the putative contributor to the multiple antibiotic-resistant P. aeruginosa infections in healthcare organizations in the province of Babil.